Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Abivax SA - American Depositary Shares (NQ:ABVX)

124.99 -1.63 (-1.29%)
Streaming Delayed Price Updated: 3:48 PM EDT, Mar 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 590,065
Open 126.01
Bid (Size) 124.92 (200)
Ask (Size) 124.99 (1,800)
Prev. Close 126.62
Today's Range 122.26 - 126.01
52wk Range 4.770 - 148.83
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
This Investor Sold $104 Million of Nuvalent Stock Amid Cancer Drug Developer's Nearly 30% Rally ↗
Nuvalent develops targeted therapies for drug-resistant cancers, advancing clinical-stage candidates in precision oncology. 
Via The Motley Fool
News headline image
This Biotech Attracted a $181 Million Investment During a Staggering 1,300% Stock Rally ↗
This clinical-stage biotech develops small-molecule therapies targeting NASH, obesity, and related metabolic diseases. 
Via The Motley Fool

Performance

YTD
-6.6%
-6.6%
1 Month
-0.5%
-0.5%
3 Month
+12.6%
+12.6%
6 Month
+51.9%
+51.9%
1 Year
+1983.2%
+1983.2%

More News

Read More
News headline image
This Fund Bought $28 Million of a Beaten-Down Immunotherapy Stock Last Quarter. What Should Long-Term Investors Know? ↗
Via The Motley Fool
Topics Regulatory Compliance
ABVX Soars Pre-Market On Reports Of $17.5 Billion Eli Lilly Takeover Interest ↗
Via Stocktwits
News headline image
This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Biotech Stock Up Nearly 300% Draws $68.7 Million Bet as Breast Cancer Drug Targets 2027 Launch ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Biotech Stock Up 700% Is Still a Top Holding Despite a $9.3 Million Sale Last Quarter ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
What to Know About This Obesity Drug Developer That Just Drew a New $7 Million Investment ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Biotech With a Breakout MS Drug Draws $8 Million Investment Amid 30% Stock Drop ↗
Via The Motley Fool
News headline image
This Biotech Stock Surged 75% Last Quarter and Pulled a New $9 Million Investment ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Life Sciences Supplier Has Plunged 50% in a Year, but One Fund Bought Up $28 Million More in Stock ↗
Via The Motley Fool
Topics Regulatory Compliance Supply Chain
News headline image
Billionaire Steve Cohen Owns Shares of This Stock That Has Soared 1,600% in The Past Year ↗
Via The Motley Fool
News headline image
2 Reasons Abivax Stock Could 10X by 2036 ↗
Via The Motley Fool
News headline image
Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026
From Abivax
Via GlobeNewswire
News headline image
Biotech Exit: $26 Million Arcellx Sale Follows Tepid Stock Performance and Kelonia Competition ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Cogent Biosciences Stock Up 346% as Fund Builds $29 Million Stake After November Phase 3 Breakthrough ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Fund Discloses $35 Million Biotech Buy Amid Staggering 830% Terns Stock Surge ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Biotech Stock Up 266%: This New $55 Million Bet Signals Conviction in Praxis Amid Pipeline Progress ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Apogee Stock Jumps 87% in One Year as This Biotech Fund Lifts Stake to $93 Million ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon. ↗
Via The Motley Fool
News headline image
Better Long-Term Buy: This Emerging Player or the Industry Leader? ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Prediction: This Healthcare Stock Could Soar by 72% in 2026 ↗
Via The Motley Fool
Top movers in Monday's pre-market session ↗
Via Chartmill
News headline image
Abivax Provides 2026 Corporate Outlook
From Abivax
Via GlobeNewswire
News headline image
Is Cidara Therapeutics a Buy After HighVista Strategies Initiated a Position in the Stock? ↗
Via The Motley Fool
Topics Regulatory Compliance

Frequently Asked Questions

Is Abivax SA - American Depositary Shares publicly traded?
Yes, Abivax SA - American Depositary Shares is publicly traded.
What exchange does Abivax SA - American Depositary Shares trade on?
Abivax SA - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Abivax SA - American Depositary Shares?
The ticker symbol for Abivax SA - American Depositary Shares is ABVX on the Nasdaq Stock Market
What is the current price of Abivax SA - American Depositary Shares?
The current price of Abivax SA - American Depositary Shares is 124.99
When was Abivax SA - American Depositary Shares last traded?
The last trade of Abivax SA - American Depositary Shares was at 03/18/26 03:48 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.